Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for NOTV, AMZN and TGTX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Friday, 05 August 2022 06:35 PM

Levi & Korsinsky, LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / August 5, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

NOTV Shareholders Click Here: https://www.zlk.com/pslra-1/inotiv-lawsuit-loss-submission-form?prid=30632&wire=1
AMZN Shareholders Click Here: https://www.zlk.com/pslra-1/amazon-com-inc-information-request-form?prid=30632&wire=1
TGTX Shareholders Click Here: https://www.zlk.com/pslra-1/tg-therapeutics-loss-submission-form?prid=30632&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Friday, August 5, 2022, Press release picture

Inotiv, Inc. (NASDAQ:NOTV)

NOTV Lawsuit on behalf of: investors who purchased September 21, 2021 - June 13, 2022
Lead Plaintiff Deadline : August 22, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/inotiv-lawsuit-loss-submission-form?prid=30632&wire=1

According to the filed complaint, during the class period, Inotiv, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Inotiv's acquisition, Envigo RMS, LL ("Envigo"), and Inotiv's Cumberland, Virginia facility (the "Cumberland Facility") engaged in widespread and flagrant violations of the Animal Welfare Act ("AWA"); (2) Envigo and Inotiv's Cumberland Facility continuously violated the AWA; (3) Envigo and Inotiv did not properly remedy issues with regards to animal welfare at the Cumberland Facility; (4) as a result, Inotiv was likely to face increased scrutiny and governmental action; (5) Inotiv would imminently shut down two facilities, including the Cumberland Facility; (6) Inotiv did not engage in proper due diligence; and (7) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Amazon.com, Inc. (NASDAQ:AMZN)

This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired shares of Amazon common stock between July 30, 2021, and April 28, 2022, inclusive.
Lead Plaintiff Deadline : September 6, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/amazon-com-inc-information-request-form?prid=30632&wire=1

According to the filed complaint, 1) defendants knew or recklessly disregarded that the Company's infrastructure and fulfillment network investments substantially outpaced demand; 2) those investments were a massive, self-imposed, undue drain on Amazon's financial condition; 3) contrary to defendants' public statements and undisclosed to investors, defendants had already implemented cutbacks to Amazon's fulfillment capacity by July 2021; and 4) as a result of defendants' misrepresentations and omissions, Amazon's common stock traded at artificially inflated prices during the class period.

TG Therapeutics, Inc. (NASDAQ:TGTX)

TGTX Lawsuit on behalf of: investors who purchased January 15, 2020 - May 31, 2022
Lead Plaintiff Deadline : September 16, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tg-therapeutics-loss-submission-form?prid=30632&wire=1

According to the filed complaint, during the class period, TG Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom

Contact Us Today


If you have questions or want to learn more about our products, our team’s here to help!

Share by: